AQST - Blueprint European Approval And Other News: The Good Bad And Ugly Of Biopharma September, 29 2020 03:40 AM Aquestive Therapeutics Inc. Blueprint gets European Union nod for Ayvakyt. Aquestive receives CRL for seizure clusters treatment Libervant. PMV Pharma makes impressive IPO debut, stock soars. For further details see: Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma